CN116849364A - 一种复合型益生菌及其制备方法 - Google Patents
一种复合型益生菌及其制备方法 Download PDFInfo
- Publication number
- CN116849364A CN116849364A CN202310570447.1A CN202310570447A CN116849364A CN 116849364 A CN116849364 A CN 116849364A CN 202310570447 A CN202310570447 A CN 202310570447A CN 116849364 A CN116849364 A CN 116849364A
- Authority
- CN
- China
- Prior art keywords
- probiotics
- parts
- composite
- immunity
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 84
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 84
- 239000002131 composite material Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 20
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 14
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 13
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 13
- 102000008186 Collagen Human genes 0.000 claims abstract description 13
- 108010035532 Collagen Proteins 0.000 claims abstract description 13
- 229920001436 collagen Polymers 0.000 claims abstract description 13
- 230000000529 probiotic effect Effects 0.000 claims abstract description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 13
- 241000894006 Bacteria Species 0.000 claims abstract description 10
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 20
- 235000013406 prebiotics Nutrition 0.000 claims description 19
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 13
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 13
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 12
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 12
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 12
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 12
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 12
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 12
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 11
- 229920001100 Polydextrose Polymers 0.000 claims description 11
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 11
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 11
- 239000000832 lactitol Substances 0.000 claims description 11
- 229960003451 lactitol Drugs 0.000 claims description 11
- 235000010448 lactitol Nutrition 0.000 claims description 11
- 239000001259 polydextrose Substances 0.000 claims description 11
- 229940035035 polydextrose Drugs 0.000 claims description 11
- 235000013856 polydextrose Nutrition 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 6
- 238000000465 moulding Methods 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 238000009461 vacuum packaging Methods 0.000 claims description 5
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 abstract description 25
- 230000036039 immunity Effects 0.000 abstract description 19
- 150000001875 compounds Chemical class 0.000 abstract description 15
- 230000001105 regulatory effect Effects 0.000 abstract description 8
- 244000052616 bacterial pathogen Species 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 230000035755 proliferation Effects 0.000 abstract description 6
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 3
- 230000008855 peristalsis Effects 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 22
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 241000305071 Enterobacterales Species 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 241000194033 Enterococcus Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000036541 health Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/23—Lactobacillus acidophilus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及益生菌食品领域,具体涉及一种复合型益生菌及其制备方法,用于解决市场上缺乏能够改善人体肠道菌群、改善肠道环境,抑制致病菌生长,调节人体免疫,促进免疫提升的复合型益生菌的问题;该复合型益生菌中利用五种益生菌合理复配,能够对调节肠道菌群、改善肠道环境,利用三种益生元可以增殖肠道有益菌群,促进肠道蠕动,添加胶原蛋白肽、酵母β‑葡聚糖两种功能性原料能够赋予其调节免疫、抗感染等多种功效,进而调节人体免疫,促进免疫提升;因此,该复合型益生菌能够调节人体肠道菌群、改善肠道环境,可抑制致病菌生长,促进优势菌增殖,还能调节人体免疫,促进免疫提升。
Description
技术领域
本发明涉及益生菌食品领域,具体涉及一种复合型益生菌及其制备方法。
背景技术
肠道被喻为人体的“第二大脑”,也是人体最大的消化器官,肠道疾病与人体健康息息相关,肠道疾病以炎症性肠病居多,它是一种非传染性疾病,会引起腹泻、腹痛、便血、呕吐和营养不良等症状,严重时诱发结肠癌。
益生菌是一类通过定植在人体内,改变其菌群组成,并对其产生有益作用的活性微生物,当摄入一定数量益生菌后,能促进肠道有益菌增殖,进而调节宿主肠道内菌群,肠道菌群在宿主中参与营养物质分解、调控代谢、维稳免疫系统等多方面生理活动,从而影响炎症反应发生。
随着健康意识的增强,人们疾病医学的理念逐渐从治疗转向预防,但是,目前市场上缺乏能够改善人体肠道菌群、改善肠道环境,抑制致病菌生长,调节人体免疫,促进免疫提升的复合型益生菌。
发明内容
为了克服上述的技术问题,本发明的目的在于提供一种复合型益生菌及其制备方法:通过将益生菌、益生元、功能性原料以及辅料加入至混合机中搅拌混合,之后过筛,得到混合料,将混合料真空包装、封袋成型,得到复合型益生菌,解决了市场上缺乏能够改善人体肠道菌群、改善肠道环境,抑制致病菌生长,调节人体免疫,促进免疫提升的复合型益生菌的问题。
本发明的目的可以通过以下技术方案实现:
一种复合型益生菌的制备方法,包括以下步骤:
步骤一:按照重量份称取益生菌15-35份、益生元30-40份、功能性原料1.5-3.5份以及辅料15-25份,备用;
步骤二:将益生菌、益生元、功能性原料以及辅料加入至混合机中,在搅拌速率为150-350r/min的条件下搅拌混合1-2h,之后过100-150目筛,得到混合料;
步骤三:将混合料真空包装、封袋成型,得到该复合型益生菌。
作为本发明进一步的方案:所述复合型益生菌内水分≤3%。
作为本发明进一步的方案:所述复合型益生菌内不得检出金黄色葡萄球菌。
作为本发明进一步的方案:一种复合型益生菌,包括以下重量份组分:
益生菌15-35份、益生元30-40份、功能性原料1.5-3.5份以及辅料15-25份。
作为本发明进一步的方案:所述益生菌包括植物乳杆菌LP45、嗜酸乳杆菌La28、嗜热链球菌S131、罗伊氏乳杆菌L840、格氏乳杆菌L838;
作为本发明进一步的方案:所述益生元包括低聚异麦芽糖、乳糖醇、聚葡萄糖。
作为本发明进一步的方案:所述功能性原料包括胶原蛋白肽、酵母β-葡聚糖。
作为本发明进一步的方案:所述辅料包括柠檬酸、柳橙水果粉。
作为本发明进一步的方案:所述植物乳杆菌LP45、嗜酸乳杆菌La28、嗜热链球菌S131、罗伊氏乳杆菌L840、格氏乳杆菌L838的质量比为3-17:5-11:5-9:1-3:1-3。
作为本发明进一步的方案:所述低聚异麦芽糖、乳糖醇、聚葡萄糖的质量比为10-15:10-20:15-25。
作为本发明进一步的方案:所述胶原蛋白肽、酵母β-葡聚糖的质量比为10-15:0.5-1。
作为本发明进一步的方案:所述柠檬酸、柳橙水果粉的质量比为1.5-7.5:5-20。
作为本发明进一步的方案:益生菌的作用机理如下:
植物乳杆菌LP45能够调节肠道菌群,抑制肠道致病菌,维护肠道屏障功能,促进肠内有益菌增殖;
嗜酸乳杆菌La28可以实现很好的抗流感病毒的作用;有效消除因流感病毒感染引起的炎症以及修复因流感病毒感染造成的肺部损伤;
嗜热链球菌S131具有较高的黏附能力和产胞外多糖的能力;能够显著促进RAW264.7巨噬细胞的增殖和吞噬能力;能够调节巨噬细胞分泌细胞因子TNF-α、IL-6、IL-10的量,提高机体免疫;
罗伊氏乳杆菌L840对肠黏膜具有很强的黏附能力,可改善肠道菌群分布,拮抗有害菌定植,避免罹患肠道疾病,罗伊氏乳杆菌L840能产生一种被称为“罗伊氏菌素”的非蛋白质类广谱抗菌物质,能广泛抑制革兰氏阳性菌、革兰氏阴性菌、酵母、真菌和病原虫等的生长,罗伊氏乳杆菌益生菌制剂可改善人体机能,提高免疫力从而促进人体健康;
格氏乳杆菌L838的作用与功效主要是帮助肠道消化吸收,有效地帮助清除胃内食物,避免胃酸分泌过多,缓解胃部压力,能够有效地帮助肠道蠕动,调节肠道菌群,起到较好的治疗效果。
本发明的有益效果:
本发明的一种复合型益生菌及其制备方法,通过将益生菌、益生元、功能性原料以及辅料加入至混合机中搅拌混合,之后过筛,得到混合料,将混合料真空包装、封袋成型,得到复合型益生菌;该复合型益生菌中利用植物乳杆菌LP45、嗜酸乳杆菌La28、嗜热链球菌S131、罗伊氏乳杆菌L840、格氏乳杆菌L838五种益生菌合理复配,能够对调节肠道菌群、改善肠道环境,利用低聚异麦芽糖、乳糖醇、聚葡萄糖三种益生元可以增殖肠道有益菌群,促进肠道蠕动,不选用蔗糖、葡萄糖等原料,血糖高人群亦可放心食用,添加胶原蛋白肽、酵母β-葡聚糖两种功能性原料,胶原蛋白肽具有恢复、修复细胞的功能,能增进细胞活力,增加皮肤亮泽;维持皮肤锁水保湿,赋予其养颜护肤、提高免疫力的效果,酵母β-葡聚糖通过特异性结合到巨噬细胞表面受体,激活巨噬细胞,分泌IL、α-IFN、TNF等从而达到调节免疫、抗感染等多种功效,进而调节人体免疫,促进免疫提升;因此,该复合型益生菌能够调节人体肠道菌群、改善肠道环境,可抑制致病菌生长,促进优势菌增殖,还能调节人体免疫,促进免疫提升。
具体实施方式
下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其它实施例,都属于本发明保护的范围。
实施例1:
本实施例为一种复合型益生菌的制备方法,包括以下步骤:
步骤一:按照重量份称取益生菌15份、益生元30份、功能性原料1.5份以及辅料15份,备用;其中,所述益生菌包括植物乳杆菌LP45、嗜酸乳杆菌La28、嗜热链球菌S131、罗伊氏乳杆菌L840、格氏乳杆菌L838;所述植物乳杆菌LP45、嗜酸乳杆菌La28、嗜热链球菌S131、罗伊氏乳杆菌L840、格氏乳杆菌L838的质量比为3:5:5:1:1;所述益生元包括低聚异麦芽糖、乳糖醇、聚葡萄糖;所述低聚异麦芽糖、乳糖醇、聚葡萄糖的质量比为10:10:15;所述功能性原料包括胶原蛋白肽、酵母β-葡聚糖;所述胶原蛋白肽、酵母β-葡聚糖的质量比为10:0.5;
步骤二:将益生菌、益生元、功能性原料以及辅料加入至混合机中,在搅拌速率为150r/min的条件下搅拌混合1h,之后过100目筛,得到混合料;
步骤三:将混合料真空包装、封袋成型,得到该复合型益生菌。
实施例2:
本实施例为一种复合型益生菌的制备方法,包括以下步骤:
步骤一:按照重量份称取益生菌25份、益生元35份、功能性原料2.5份以及辅料20份,备用;其中,所述益生菌包括植物乳杆菌LP45、嗜酸乳杆菌La28、嗜热链球菌S131、罗伊氏乳杆菌L840、格氏乳杆菌L838;所述植物乳杆菌LP45、嗜酸乳杆菌La28、嗜热链球菌S131、罗伊氏乳杆菌L840、格氏乳杆菌L838的质量比为10:8:7:2:2;所述益生元包括低聚异麦芽糖、乳糖醇、聚葡萄糖;所述低聚异麦芽糖、乳糖醇、聚葡萄糖的质量比为12.5:15:20;所述功能性原料包括胶原蛋白肽、酵母β-葡聚糖;所述胶原蛋白肽、酵母β-葡聚糖的质量比为12.5:0.75;
步骤二:将益生菌、益生元、功能性原料以及辅料加入至混合机中,在搅拌速率为250r/min的条件下搅拌混合1.5h,之后过125目筛,得到混合料;
步骤三:将混合料真空包装、封袋成型,得到该复合型益生菌。
实施例3:
本实施例为一种复合型益生菌的制备方法,包括以下步骤:
步骤一:按照重量份称取益生菌35份、益生元40份、功能性原料3.5份以及辅料25份,备用;其中,所述益生菌包括植物乳杆菌LP45、嗜酸乳杆菌La28、嗜热链球菌S131、罗伊氏乳杆菌L840、格氏乳杆菌L838;所述植物乳杆菌LP45、嗜酸乳杆菌La28、嗜热链球菌S131、罗伊氏乳杆菌L840、格氏乳杆菌L838的质量比为17:11:9:3:3;所述益生元包括低聚异麦芽糖、乳糖醇、聚葡萄糖;所述低聚异麦芽糖、乳糖醇、聚葡萄糖的质量比为15:20:25;所述功能性原料包括胶原蛋白肽、酵母β-葡聚糖;所述胶原蛋白肽、酵母β-葡聚糖的质量比为15:1;
步骤二:将益生菌、益生元、功能性原料以及辅料加入至混合机中,在搅拌速率为350r/min的条件下搅拌混合2h,之后过150目筛,得到混合料;
步骤三:将混合料真空包装、封袋成型,得到该复合型益生菌。
将实施例1-3的复合型益生菌进行检测,检测结果如下表所示:
样品 | 实施例1 | 实施例2 | 实施例3 |
含水量,% | 2.17 | 2.05 | 1.91 |
是否检出金黄色葡萄球菌 | 否 | 否 | 否 |
将实施例3的复合型益生菌进行动物实验,挑选40只体重相近的SPF级雄性NIH小鼠,随机均分为4组,分别标记为低剂量组、中剂量组、高剂量组以及空白组,将复合型益生菌溶解于纯净水中,分别形成低剂量溶液、中剂量溶液、高剂量溶液,取1mL低剂量溶液、中剂量溶液、高剂量溶液分别给低剂量组、中剂量组、高剂量组的SPF级雄性NIH小鼠进行灌胃,其中,低剂量溶液、中剂量溶液、高剂量溶液中分别含有0.25g、0.5g、0.75g复合型益生菌,向空白组的SPF级雄性NIH小鼠进行灌胃1mL纯净水;
每日一次,连续灌胃30d,并对小鼠体重、肠杆菌以及肠球菌进行检测,检测结果如下表所示:
参阅上表数据,根据体重变化可以得知,所有小鼠均未见明显异常,体重缓慢增长,而且喂食复合型益生菌的小鼠较空白组的小鼠体重相近,无明显异常,表明复合型益生菌对小鼠的生长发育无不良影响;根据肠杆菌变化可以得知,喂食复合型益生菌的小鼠较空白组的小鼠肠杆菌变化更加明显,且随着剂量的增加差距明显增大,喂食复合型益生菌后小鼠体内肠杆菌菌落数显著减少,表明复合型益生菌对小鼠肠杆菌菌落具有抑制作用;根据肠球菌变化可以得知,喂食复合型益生菌的小鼠较空白组的小鼠肠球菌变化更加明显,且随着剂量的增加差距明显增大,喂食复合型益生菌后小鼠体内肠球菌菌落数显著减少,表明复合型益生菌对小鼠肠球菌菌落具有抑制作用;综上所述,复合型益生菌对小鼠生长发育无不利印象,但是能够调节小鼠体内菌落,复合型益生菌具有调节肠道菌群功能,可抑制致病菌生长,促进优势菌增殖。
在本说明书的描述中,参考术语“一个实施例”、“示例”、“具体示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中,对上述术语的示意性表述不一定指的是相同的实施例或示例。而且,描述的具体特征、结构、材料或者特点可以在任何的一个或多个实施例或示例中以合适的方式结合。
以上内容仅仅是对本发明所作的举例和说明,所属本技术领域的技术人员对所描述的具体实施例做各种各样的修改或补充或采用类似的方式替代,只要不偏离发明或者超越本权利要求书所定义的范围,均应属于本发明的保护范围。
Claims (10)
1.一种复合型益生菌的制备方法,其特征在于,包括以下步骤:
步骤一:按照重量份称取益生菌15-35份、益生元30-40份、功能性原料1.5-3.5份以及辅料15-25份,备用;
步骤二:将益生菌、益生元、功能性原料以及辅料加入至混合机中,在搅拌速率为150-350r/min的条件下搅拌混合1-2h,之后过100-150目筛,得到混合料;
步骤三:将混合料真空包装、封袋成型,得到该复合型益生菌。
2.根据权利要求1所述的一种复合型益生菌的制备方法,其特征在于,所述复合型益生菌内水分≤3%。
3.根据权利要求1所述的一种复合型益生菌的制备方法,其特征在于,所述复合型益生菌内不得检出金黄色葡萄球菌。
4.一种复合型益生菌,其特征在于,包括以下重量份组分:
益生菌15-35份、益生元30-40份、功能性原料1.5-3.5份以及辅料15-25份;
所述益生菌包括植物乳杆菌LP45、嗜酸乳杆菌La28、嗜热链球菌S131、罗伊氏乳杆菌L840、格氏乳杆菌L838;
所述益生元包括低聚异麦芽糖、乳糖醇、聚葡萄糖。
5.根据权利要求4所述的一种复合型益生菌,其特征在于,所述植物乳杆菌LP45、嗜酸乳杆菌La28、嗜热链球菌S131、罗伊氏乳杆菌L840、格氏乳杆菌L838的质量比为3-17:5-11:5-9:1-3:1-3。
6.根据权利要求4所述的一种复合型益生菌,其特征在于,所述低聚异麦芽糖、乳糖醇、聚葡萄糖的质量比为10-15:10-20:15-25。
7.根据权利要求4所述的一种复合型益生菌,其特征在于,所述功能性原料包括胶原蛋白肽、酵母β-葡聚糖。
8.根据权利要求7所述的一种复合型益生菌,其特征在于,所述胶原蛋白肽、酵母β-葡聚糖的质量比为10-15:0.5-1。
9.根据权利要求4所述的一种复合型益生菌,其特征在于,所述辅料包括柠檬酸、柳橙水果粉。
10.根据权利要求9所述的一种复合型益生菌,其特征在于,所述柠檬酸、柳橙水果粉的质量比为1.5-7.5:5-20。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310570447.1A CN116849364A (zh) | 2023-05-19 | 2023-05-19 | 一种复合型益生菌及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310570447.1A CN116849364A (zh) | 2023-05-19 | 2023-05-19 | 一种复合型益生菌及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116849364A true CN116849364A (zh) | 2023-10-10 |
Family
ID=88229246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310570447.1A Pending CN116849364A (zh) | 2023-05-19 | 2023-05-19 | 一种复合型益生菌及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116849364A (zh) |
-
2023
- 2023-05-19 CN CN202310570447.1A patent/CN116849364A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101541194B (zh) | 口服益生菌剂型 | |
CN108991327A (zh) | 一种益生菌固体饮料及其制备方法 | |
CN112869170A (zh) | 可提高胃肠道免疫能力的益生菌益生元营养组合物及应用 | |
CN111254088A (zh) | 一种凝结芽孢杆菌菌株及其应用 | |
CN111000247B (zh) | 一种复合益生菌粉的制备方法 | |
CN108935970A (zh) | 一种含壳寡糖的无抗饲料功能产品、其制备方法及应用 | |
CN104543410B (zh) | 一种保健抗病猪饲料添加剂及其制备方法 | |
CN115381860A (zh) | 一种保护酒精性肝损伤组合物及其制备方法与应用 | |
CN116855413B (zh) | 利用鼠李糖乳杆菌YSs069制备调节人体微生态平衡的生物活性物质及其应用 | |
CN112438402A (zh) | 一种复合益生菌及其制备方法 | |
CN106617095B (zh) | 一种阿胶益生菌口服液及其制备方法 | |
CN110710627A (zh) | 一种功能性益生菌固体饮料及其制备方法 | |
CN116966240A (zh) | 一种分解核酸物质降低体内尿酸生成组合物的制备方法 | |
CN111150059A (zh) | 一种女性专用益生菌组台物及其应用 | |
CN116849364A (zh) | 一种复合型益生菌及其制备方法 | |
CN113397170B (zh) | 一种用于调节人体肠道菌群的海洋益生元组合物的应用 | |
CN115011513A (zh) | 一种增强免疫并调解肠胃控制脂肪及减肥排毒的乳酸菌粉 | |
CN112674203B (zh) | 一种可降解赭曲霉毒素的微生态制剂及其制备方法 | |
CN113575959A (zh) | 一种能够抑制有害菌的益生菌组合物 | |
CN113812537A (zh) | 促进围产期母猪胃肠道健康的微生态制剂及其制备方法 | |
CN113995139A (zh) | 一种益生菌组合物及其应用 | |
CN116076729A (zh) | 一种组合物以及含有该组合物的食品和药品 | |
CN112999305A (zh) | 一种调节肠道菌群紊乱的固体制剂及其制备方法 | |
CN111990648A (zh) | 一种护胃养胃的益生菌粉及其制备方法 | |
CN113712207A (zh) | 提高胃肠道免疫能力的益生菌益生元组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |